Loading...
Zydus Lifesciences Secures USFDA Approval for Generic Anti-Parasitic, Leprosy Drugs
LIVE TV
LOCAL
Tour
ENGLISH
For You
Entertainment
National
Sports
Markets
Business & Economy
Lifestyle
World
Astrology & Religion
Technology
Education & Jobs
Auto
Politics
Viral
Opinions
Loading more articles...
Home
Local
Live TV
Zydus Lifesciences Secures USFDA Nod for Generic Anti-Parasitic, Leprosy Drugs
N
News18
•
28-02-2026, 16:15
Zydus Lifesciences Secures USFDA Nod for Generic Anti-Parasitic, Leprosy Drugs
•
Zydus Lifesciences received USFDA approval for generic Ivermectin Tablets (3 mg) and Dapsone Tablets (25 mg and 100 mg).
•
Ivermectin tablets are anti-parasitic medications for intestinal strongyloidiasis and onchocerciasis.
•
Dapsone tablets are indicated for treating leprosy and dermatitis herpetiformis.
•
Dapsone acts as an anti-infective and antibacterial agent, controlling skin lesions in dermatitis herpetiformis and leprosy.
Read Full Article on News18 in English
✦
More like this
✦
More like this
Zydus, Lupin Partner to Co-Market Diabetes Drug Semaglutide in India
N
News18
Indoco Remedies Shares Soar 7% on USFDA Approval for Brivaracetam Oral Solution
C
CNBC TV18
Biocon Pharma secures US FDA nod for generic Liraglutide (gVictoza) injection
C
CNBC TV18
Zydus Lifesciences' Desidustat gets China NMPA approval for renal anaemia
N
News18
Biocon gets USFDA nod for Liraglutide injection gSaxenda for weight management
C
CNBC TV18
Alembic Pharma gets USFDA nod for anti-seizure drug, stock volatile
C
CNBC TV18